Bristol Myers Squibb【BMY】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

59.0043

買値

売値

出来高

11,578,946

58.53 日の範囲 59.685

39.35 52 週間の範囲 63.33

時価総額

119.738B

前日終値

59.19

始値

59.32

時刻

254

59.0043

(formt)

最終取引時間

財務取引量

US$ 684,609,652

VWAP

59.1254

平均取引量 (3 か月)

11,651,302

発行済株式数

2,029,312,023

配当利回り

4.20%

PER

-13.43

1 株当たり利益 (EPS)

-4.41

歳入

48.3B

純利益

-8.95B

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.bms.com

本社

Wilmington, Delaware, USA

設立

Bristol Myers Squibb Co is listed in the Pharmaceutical Preparations sector of the ニューヨーク証券取引所 with ticker BMY. The last closing price for Bristol Myers Squibb was US$59.19. Over the last year, Bristol Myers Squibb shares have traded in a share price range of US$ 39.35 to US$ 63.33.

Bristol Myers Squibb currently has 2,029,312,023 shares in issue. The market capitalisation of Bristol Myers Squibb is US$120.11 billion. Bristol Myers Squibb has a price to earnings ratio (PE ratio) of -13.43.

全体の流れ

ベアリッシュ

ネットプレミアム

-2M

Calls / Puts

56.25%

買い / 売り

161.11%

OTM / ITM

316.67%

Sweeps比率

10.00%

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc. PR Newswire NEW YORK, March 11, 2025 NEW YORK, March 11, 2025...

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free...

Form 4 - Statement of changes in beneficial ownership of securities

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which...

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile...

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the...

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate With these data, Breyanzi demonstrates...

Form 8-K - Current report

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+9...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.8557	-1.42950217173	59.86	61.49	59	13861918	60.5360523	CS
4	0.8443	1.45168500688	58.16	63.33	56.96	12960224	60.31142554	CS
12	2.0843	3.66180604357	56.92	63.33	53.54	11651302	58.41886664	CS
26	9.1843	18.4349658772	49.82	63.33	49.715	11255674	56.98780037	CS
52	6.6343	12.6681306091	52.37	63.33	39.35	12646026	50.45851541	CS
156	-14.1957	-19.3930327869	73.2	81.435	39.35	11830536	59.48971853	CS
260	8.5443	16.9328180737	50.46	81.435	39.35	11911866	60.56251379	CS

BMY - Frequently Asked Questions (FAQ)

What is the current Bristol Myers Squibb share price?

The current share price of Bristol Myers Squibb is US$ 59.0043

How many Bristol Myers Squibb shares are in issue?

Bristol Myers Squibb has 2,029,312,023 shares in issue

What is the market cap of Bristol Myers Squibb?

The market capitalisation of Bristol Myers Squibb is USD 120.11B

What is the 1 year trading range for Bristol Myers Squibb share price?

Bristol Myers Squibb has traded in the range of US$ 39.35 to US$ 63.33 during the past year

What is the PE ratio of Bristol Myers Squibb?

The price to earnings ratio of Bristol Myers Squibb is -13.43

What is the cash to sales ratio of Bristol Myers Squibb?

The cash to sales ratio of Bristol Myers Squibb is 2.49

What is the reporting currency for Bristol Myers Squibb?

Bristol Myers Squibb reports financial results in USD

What is the latest annual turnover for Bristol Myers Squibb?

The latest annual turnover of Bristol Myers Squibb is USD 48.3B

What is the latest annual profit for Bristol Myers Squibb?

The latest annual profit of Bristol Myers Squibb is USD -8.95B

What is the registered address of Bristol Myers Squibb?

The registered address for Bristol Myers Squibb is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Bristol Myers Squibb website address?

The website address for Bristol Myers Squibb is www.bms.com

Which industry sector does Bristol Myers Squibb operate in?

Bristol Myers Squibb operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
WORWorthington Enterprises Inc	US$ 51.60 (23.95%)	1.92M
XYFX Financial	US$ 15.29 (17.62%)	502.02k
BEDUBright Scholar Education Holdings Limited	US$ 1.72 (12.42%)	18.94k
BAKBraskem SA	US$ 4.125 (11.79%)	2.15M
GMEGameStop Corp Holding Company	US$ 28.385 (11.75%)	53.31M
KUKEKuke Music Holding Limited	US$ 2.44 (-17.29%)	34.72k
GCTSWts each whole warrant exercisable one share of Common Stock	US$ 1.735 (-16.99%)	274.39k
BALYBallys Corporation	US$ 14.00 (-13.37%)	27.85k
VRTVertiv Holdings LLC	US$ 81.6109 (-10.89%)	19.01M
IHiHuman Inc	US$ 2.26 (-10.67%)	45.71k
FFord Motor Company	US$ 10.30 (0.10%)	140.98M
QBTSD Wave Quantum Inc	US$ 8.2762 (-5.74%)	63.51M
NIONIO Inc	US$ 4.225 (-3.76%)	62.93M
BTEBaytex Energy Corporation	US$ 2.255 (-2.38%)	53.37M
GMEGameStop Corp Holding Company	US$ 28.385 (11.75%)	53.31M